Eli Lilly and Co (LLY.N)

LLY.N on New York Stock Exchange

53.50USD
4:00pm EDT
Price Change (% chg)

$0.39 (+0.73%)
Prev Close
$53.11
Open
$53.37
Day's High
$53.66
Day's Low
$53.12
Volume
865,191
Avg. Vol
1,402,936
52-wk High
$58.40
52-wk Low
$42.10

LLY.N

Chart for LLY.N

About

Eli Lilly and Company discovers, develops, manufactures, and sells products, in one business segment, pharmaceutical products. The Company also has an animal health business segment. It manufactures and distributes its products through facilities in the United States, Puerto Rico, and 15 other countries. Its products are sold in... (more)

Overall

Beta: 0.75
Market Cap (Mil.): $59,835.73
Shares Outstanding (Mil.): 1,126.64
Dividend: 0.49
Yield (%): 3.69

Financials

  LLY.N Industry Sector
P/E (TTM): 11.91 37.93 37.76
EPS (TTM): 4.46 -- --
ROI: 19.63 19.48 18.76
ROE: 33.23 20.17 19.59
Search Stocks

WRAPUP 1-Drugmakers fear short-term "turmoil" as China probes widen

* AstraZeneca CEO sees short-term disruption, price pressure

8:28am EDT

Eli Lilly to freeze employee base pay ahead of generic onslaught

NEW YORK - U.S. drugmaker Eli Lilly & Co , which expects to lose about 20 percent of its global revenue next year due to the expiration of key drug patents, is suspending base pay increases for most employees in 2014 to cut costs.

17 Jul 2013

Medicare plan on Alzheimer's test dismays advocates

CHICAGO - Alzheimer's experts plan to protest proposed Medicare guidelines that would deny coverage of an Eli Lilly diagnostic test for the disease unless patients are taking part one of several clinical trials in which the $3,000 test is being used.

09 Jul 2013

UPDATE 1-Medicare plan on Alzheimer's test dismays advocates

CHICAGO, July 9 - Alzheimer's experts plan to protest proposed Medicare guidelines that would deny coverage of an Eli Lilly diagnostic test for the disease unless patients are taking part one of several clinical trials in which the $3,000 test is being used.

09 Jul 2013

Lilly CEO returns to work after surgery

July 8 - Eli Lilly and Co said Chief Executive John Lechleiter returned to work after recovering from a surgery to treat a dilated aorta.

08 Jul 2013

FDA probes deaths of two patients on Lilly schizophrenia drug

- The Food and Drug Administration is investigating the cases of two individuals who died after injections with Eli Lilly and Co's long-acting treatment for schizophrenia, Zyprexa Relprevv.

18 Jun 2013

Lilly CEO recovering after repair to aorta

- John Lechleiter, the longtime chief executive of Eli Lilly and Co, is recovering from successful surgery to repair a dilated aorta, the U.S. drugmaker said on Tuesday.

14 May 2013

UPDATE 1-Eli Lilly lymphoma drug fails in late-stage trial

May 10 - Eli Lilly and Co said it will end development of an experimental cancer drug after it failed in a late-stage trial to delay a worsening of symptoms in patients with lymphoma.

10 May 2013

Lilly CEO Lechleiter to undergo surgery for dilated aorta

- Drug maker Eli Lilly and Co said Chief Executive John Lechleiter will undergo a surgery on May 13 to treat a dilated aorta but is expected to recover and return to work by this summer.

06 May 2013

Lilly profit beats forecast, helped by lower taxes

- Eli Lilly and Co on Wednesday reported higher-than-expected first-quarter earnings, helped by favorable taxes and higher sales of its treatments for diabetes, depression and lung cancer.

24 Apr 2013

Competitors

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Stock Traders Daily
$58.00
Provider: ValuEngine, Inc.
$25.00
Provider: Wright Reports
$483.00
Provider: Stock Traders Daily
$495.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks